Primary hormone treatment in postmenopausal women with breast cancer

被引：0

作者：

Escalante S.M. ^{[1
]}

Sanz V.P. ^{[1
]}

Lescure A.R. ^{[1
]}

Navarro I.B. ^{[1
]}

Mena A.C. ^{[1
]}

机构：

[1] Department of Medical Oncology, Hospital General Universitario de Elche, 03202 Elche, Alicante

来源：

Clinical and Translational Oncology | 2006年 / 8卷 / 5期

关键词：

Aromatase inhibitors; Hormone therapy; Neoadjuvant treatment; Postmenopausal women;

D O I：

10.1007/s12094-006-0185-7

中图分类号：

学科分类号：

摘要：

Clinical benefits of hormone therapy in patients with hormone-sensitive tumors have been clearly established. Postmenopausal women with positive hormone receptors represent the largest group of patients in whom early stage breast cancer is diagnosed. Third-generation aromatase inhibitors (letrozole, anastrozole, and exemestane) are active and well tolerated in postmenopausal women with hormone-sensitive metastasic or locally advanced breast cancer as first or second line treatment. These are also valuable agents in the neoadjuvant setting in postmenopausal women, and even as single treatment in localized breast tumors in women not amenable to surgery. © FESEO 2006.

引用

页码：372 / 374

页数：2

共 50 条

[21] Cognitive functioning during long-term tamoxifen treatment in postmenopausal women with breast cancer
Boele, Florien W.
Schilder, Christina M. T.
de Roode, Mari-Lou
Deijen, Jan Berend
Schagen, Sanne B.
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2015, 22 (01): : 17 - 25
[22] Aromatase inhibitors: Effective endocrine therapy in the early adjuvant setting for postmenopausal women with hormone-responsive breast cancer
Mauriac, Louis
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 20 : S15 - S29
[23] Optimizing aromatase inhibitor integration into initial treatment strategies in postmenopausal women with hormone-receptor-positive early breast cancer
Rowan T. Chlebowski
Breast Cancer Research and Treatment, 2008, 112 : 25 - 34
[24] Optimizing aromatase inhibitor integration into initial treatment strategies in postmenopausal women with hormone-receptor-positive early breast cancer
Chlebowski, Rowan T.
BREAST CANCER RESEARCH AND TREATMENT, 2008, 112 (Suppl 1) : 25 - 34
[25] Breast cancer after hormone replacement therapy - does prognosis differ in perimenopausal and postmenopausal women?
Baumgaertner, A. K.
Haeusler, A.
Seifert-Klauss, V.
Schuster, T.
Schwarz-Boeger, U.
Kiechle, M.
BREAST, 2011, 20 (05) : 448 - 454
[26] Postmenopausal hormone therapy and its association with breast cancer
Syal, Arshi
Aggarwal, Neelam
JOURNAL OF MID-LIFE HEALTH, 2020, 11 (04) : 187 - 195
[27] Adherence to hormone therapy among women with breast cancer
Claudia Brito
Margareth Crisóstomo Portela
Mauricio Teixeira Leite de Vasconcellos
BMC Cancer, 14
[28] Reproductive factors, exogenous hormone use, and risk of pancreatic cancer in postmenopausal women
Kabat, Geoffrey C.
Kamensky, Victor
Rohan, Thomas E.
CANCER EPIDEMIOLOGY, 2017, 49 : 1 - 7
[29] Rheumatic Complaints in Women Taking Aromatase Inhibitors for Treatment of Hormone-Dependent Breast Cancer
Scarpa, Raffaele
Atteno, Mariangela
Peluso, Rosario
Costa, Luisa
Padula, Stefania
Di Minno, Matteo Nicola Dario
Caso, Francesco
Iervolino, Salvatore
Vitiello, Maria
Del Puente, Antonio
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2011, 17 (04) : 169 - 172
[30] The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors
Rugo, H. S.
ANNALS OF ONCOLOGY, 2008, 19 (01) : 16 - 27

← 1 2 3 4 5 →